AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05476328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPACE
Description: SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
Study NCT05476328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FAST
Description: FAST (Fundamental Asynchronous Stimulus Timing) is a low- and variable-rate coding strategy that has been shown to be power efficient and significantly increase sensitivity to ITD cues in bilateral subjects. It also explicitly codes low F0s as the rate of stimulation and may have tone and music benefits. It has been implemented on the Nucleus 5 CP800 sound processor for CIC4-based implants.
Study NCT05476328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPAL-SPACE
Description: OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
Study NCT05476328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FAST-OPAL
Description: FAST-OPAL (combined FAST and OPAL strategy) strategy was developed to improve FAST strategy performance in noisy environments. The processing techniques employed by FAST-OPAL retain the sparse, yet temporally precise coding of temporal envelope information, while improving coding of that information in noise and coding of relative across-channel intensity in noise.
Study NCT05476328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Device Interface Tool
Description: For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
Study NCT00696111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Lupron followed by estrogen plus placebo
Description: A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
Study NCT01152580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: 3mg p.o. at bedtime daily
Study NCT01152580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: lactose p.o. at bedtime daily
Study NCT01688700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with paclitaxel and cisplatin
Description: Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy.
Study NCT04654338 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR + HDR
Description: One SABR treatment + one HDR brachytherapy treatment
Study NCT01542918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral
Study NCT01542918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)
Study NCT01057966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)
Description: Single, full strength dose tablet taken one time
Study NCT04067466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber product
Description: Fiber product with inulin, maltodextrin, gum guar and plum powder.
Study NCT04067466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo product with maltodextrin and plum powder
Study NCT00901693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-46383A Ophthalmic Solution
Study NCT00901693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-46383A Ophthalmic Solution Vehicle
Study NCT04591522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy fecal bacteria liquid
Description: Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
Study NCT02628210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: map3® Cellular Allogeneic Bone Graft
Description: Patients will receive map3® Cellular Allogeneic Bone Graft
Study NCT01397838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-Bone
Description: 500 mg Capsules of Pro-Bone twice daily
Study NCT01329367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control.
Study NCT01329367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein group
Description: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control.
Study NCT01329367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antioxidant group
Description: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control.
Study NCT04026776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
Study NCT04026776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
Study NCT04026776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
Study NCT01452750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Study NCT01452750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Study NCT01452750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
Study NCT01452750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
Study NCT01452750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Study NCT02187991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
Study NCT02187991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
Study NCT02187991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
Study NCT01835626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
Study NCT01835626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
Study NCT01952327 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The pleurapump system
Description: Implantation of the pleurapump system
Study NCT00198562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
Study NCT02576678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Study NCT03545854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
Study NCT04597268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine 1 mic/kg
Study NCT04597268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine 1mg/kg
Study NCT04597268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.05 mg/kg
Study NCT04090879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Description: 1) Altering the nicotine content of the tobacco research cigarette
Study NCT04090879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
Study NCT03076034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Point Indentation
Description: The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm.
Study NCT01548040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab XP
Description: NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
Study NCT01548040 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Quadriceps TENS
Description: on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
Study NCT04565665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT04565665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Given IV
Study NCT01959464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinone vaginal progesterone gel
Description: Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
Study NCT01959464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
Study NCT03763825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc
Description: Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
Study NCT04245631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Recombinase aided amplification (RAA) assay
Description: We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
Study NCT02404636 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Brief structured interview
Study NCT00122993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthful eating and food choices behavior change programs and changes in worksite food availability and prices
Description: Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
Study NCT00122993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity programs are offered at the intervention garages for an 18 month period.
Study NCT00122993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
Study NCT02045238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
Study NCT02045238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest X-Ray
Study NCT02045238 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chest X-Ray
Study NCT02045238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory virus screening test
Description: Immunofluorescence analysis of nasal aspirate
Study NCT02045238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory virus screening test
Description: Immunofluorescence analysis of nasal aspirate
Study NCT02639130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exendin [9-39]
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
Study NCT02639130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin [9-39]
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
Study NCT02639130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion as challenge agent
Study NCT02639130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusion as challenge agent
Study NCT01538381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib for 2 weeks at a dose of 40 mg/day
Study NCT01538381 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation
Study NCT03905889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
Study NCT03905889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
Study NCT04108468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Simponi
Study NCT00737126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Administration of a daily tablet containing 5 mg of folic acid for 4 months.
Study NCT00737126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of an oral placebo pill
Study NCT03816748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula, HFNC
Description: The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
Study NCT03028974 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
Study NCT03028974 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
Study NCT00796770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48.
Study NCT02293044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crest® Sensi-Stop™ Strips
Study NCT02351531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed formula
Study NCT02959632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
Study NCT03912558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Butterfly device implantation
Description: The Butterfly device will be positioned and deployed with cystoscopy guidance
Study NCT03950570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.